ED Management of Severe Hyperglycemia: A Clinical Trial

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

ED Management of Severe Hyperglycemia: An Open-Label Randomized Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02478190
• Other study ID #: 15-3931
• Status: Completed
• Phase: N/A
• First received: June 17, 2015
• Last updated: March 20, 2018
• Start date: June 2015
• Est. completion date: December 2017

Study information

• Verified date: March 2018
• Source: Minneapolis Medical Research Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Emergency Department (ED) patients with severe hyperglycemia will be randomized to two treatment goals: discharge glucose less than 600 mg/dL or less than 350 mg/dL.

Randomization is stratified by whether the chief complaint is "High Blood Sugar" in the electronic medical record or other.

Description:

It is common practice to provide insulin and/or intravenous (IV) fluids to lower glucose levels prior to discharge in patients that present with hyperglycemia. There is, however, no data supporting this practice.

A recent retrospective observational cohort study (HSR# 12-3497) of 567 ED patients with severe hyperglycemia demonstrated no association between discharge glucose levels and short-term adverse outcomes at 7 days (return ED visits, diabetic ketoacidosis (DKA), hospitalization, and death).

There were no other short-term adverse outcomes associated with the degree of glycemic control. Less than 1% of patients developed DKA at 7 days. No patients died.

As this was a retrospective study, the conclusions that can be drawn are limited by the lack of randomization and control; it is necessary to conduct a randomized controlled trial to quantify how much time is expended caring for these patients, and gather safety data.

This is important because much time and money is focused on glucose reduction, which may not change short-term outcomes. Furthermore, in retrospective analysis approximately 1.5% of patients receiving therapy for hyperglycemia developed iatrogenic hypoglycemia during the ED stay.

To detect a difference in length of stay by 60 minutes (Standard deviation is 100 minutes) with an p=0.05 and b=0.8, enrollment of 45 patients per group will be required, with a total enrollment of 90 patients. Enrollment will stop when 45 patients in each group have been contacted in follow-up.

This study will only include patients who are discharged from the ED. Patients who are enrolled and then eventually admitted to the hospital will be tabulated but excluded from the length of stay analysis.

Statistical analysis will be completed for the primary outcome with a Mann-Whitney U test, assuming the data will not be normally distributed. Secondary outcomes will be compared with chi-squared testing. A secondary regression model will be formed, based on covariates that could influence ED length of stay, such as amount of diagnostic testing completed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Glucose of more than 400mg/dL but less than 600 mg/dL at any point in the ED

• Working phone number and willing to discuss health status at 7-10 days via phone

Exclusion Criteria:

• Plan for hospital admission

• Already received insulin during the ED stay

• Type 1 diabetes

• Less than 18 years old

• Non-English speaking

• Altered mental status or encephalopathy (unable to provide informed consent)

• DKA, as determined clinically by the treating physician, without a lab requirement.

• Critically ill, as determined by the treating physician.

• Unable to provide informed consent

• Prisoners

• Pregnant women

Related Conditions & MeSH terms

• Complications of Diabetes Mellitus
• Diabetes Complications
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Diabetes-Related Complications
• Hyperglycemia

Intervention

Other:
• Tight control: goal glucose 350 mg/dL or lower
Goal glucose at discharge will be 350 mg/dL or less.
• Loose control: goal glucose 600 mg/dL or lower
Goal glucose at discharge will be 600 mg/dL or less.

Locations

Country	Name	City	State
United States	Hennepin County Medical Center	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Minneapolis Medical Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ED Length of Stay	Time elapsed from when the patient is roomed until the time the MD places discharge order, by review of the Electronic Medical record by a blinded abstractor.	This outcome measure is defined as the amount of time elapsed between when the patient is roomed, and when a discharge order is placed, during a single ED encounter, which is generally less than 4 hours.
Secondary	Iatrogenic hypoglycemia	Rate of iatrogenic hypoglycemia in both groups, defined as: glucose <60 or glucose less than 100 mg/dL and symptoms of hypoglycemia that resolved with food/drink, or any use of IV dextrose 50%, glucagon, or oral glucose tabs/gel	The patient will be followed during a single ED encounter, which is generally less than 4 hours.
Secondary	Return ED visit for hyperglycemia and hospital admission for any reason, excluding trauma	Composite outcome of rate of repeat ED visit for hyperglycemia or hospital admission for any reason, excluding trauma admission. ED visit for hyperglycemia defined as: chief complaint of hyperglycemia, chief complaint of polyuria, polydipsia, fatigue, blurry vision, or malaise and found to have blood glucose more than 250 mg/dL, primary ED diagnosis of hyperglycemia, or ED or hospital diagnosis of DKA or hyperosmolar syndrome.	7 days
Secondary	Return ED visit for any reason	Each patient will be assessed via chart review and telephone follow up to see if they visited an ED for any reason during the 7 day time frame. Rates of ED visits for any reason at 7 days will be compared between the two treatment arms.	7 days